Level Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Level Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$389K	Hold	6,880	–	–	0.18%	41
2025 Q4	$409K	Sell	6,880 -2,180	-24%	-$119K	0.21%	36
2025 Q3	$491K	Hold	9,060	–	–	0.26%	32
2025 Q2	$498K	Hold	9,060	–	–	0.29%	31
2025 Q1	$640K	Sell	9,060 -483	-5%	-$32.5K	0.42%	22
2024 Q4	$627K	Buy	+9,543	New	+$639K	0.44%	24

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Level Wealth Management's BMRN Position: Q1 2026 in Review

Level Wealth Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 6,880 shares worth $389K. The position accounts for 0.18% of the portfolio, ranked #41.

Level Wealth Management first reported a position in BMRN in Q4 2024 and has held it in 6 quarters since. The position peaked at $640K in Q1 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Level Wealth Management held 6,880 shares of BioMarin Pharmaceuticals worth $389K as of Q1 2026.
Level Wealth Management left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up 0.18% of Level Wealth Management's portfolio in Q1 2026, its #41 holding.
Level Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Level Wealth Management's BioMarin Pharmaceuticals position peaked at $640K in Q1 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Level Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.